Previously, it was demonstrated that treating animals with recombinant Flt3 ligand (FLt3L) increased numbers of cDC and pDC in circulation as well as in peripheral organs, which can protect animals from metastatic tumor development and prolong survival, and reverse late stage allergic responses in the lung [9]–[13]. Here, FLT3LG is linked to neoplasm.